Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Shares Outstanding (Weighted Average): 2018-2024

Historic Shares Outstanding (Weighted Average) for BridgeBio Pharma (BBIO) over the last 7 years, with Dec 2024 value amounting to $189.0 million.

  • BridgeBio Pharma's Shares Outstanding (Weighted Average) rose 1.67% to $191.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.2 million, marking a year-over-year increase of 1.67%. This contributed to the annual value of $189.0 million for FY2024, which is 8.64% up from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Shares Outstanding (Weighted Average) is $189.0 million, which was up 8.64% from $174.0 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Shares Outstanding (Weighted Average) registered a high of $189.0 million during FY2024, and its lowest value of $122.6 million during FY2020.
  • For the 3-year period, BridgeBio Pharma's Shares Outstanding (Weighted Average) averaged around $170.8 million, with its median value being $174.0 million (2023).
  • Per our database at Business Quant, BridgeBio Pharma's Shares Outstanding (Weighted Average) dropped by 0.97% in 2020 and then climbed by 20.07% in 2021.
  • BridgeBio Pharma's Shares Outstanding (Weighted Average) (Yearly) stood at $122.6 million in 2020, then climbed by 20.07% to $147.2 million in 2021, then rose by 1.57% to $149.5 million in 2022, then grew by 16.38% to $174.0 million in 2023, then increased by 8.64% to $189.0 million in 2024.